Portolan Capital Management’s Pulse Biosciences PLSE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.4M Sell
288,356
-464,977
-62% -$19.6M 0.59% 61
2026
Q2
$20.9M Buy
753,333
+19,961
+3% +$471K 0.78% 44
2026
Q1
$15.8M Buy
733,372
+339,873
+86% +$6.27M 0.84% 40
2025
Q4
$5.4M Buy
393,499
+291,302
+285% +$4.54M 0.29% 102
2025
Q3
$1.81M Buy
+102,197
New +$1.62M 0.1% 108

Other funds holding PLSE

Portolan Capital Management's PLSE Position: Q3 2026 in Review

Portolan Capital Management reduced its Pulse Biosciences (PLSE) stake by 62% in Q3 2026, selling an estimated $19.6M and leaving 288,356 shares worth $14.4M. The position accounts for 0.59% of the portfolio, ranked #61.

Portolan Capital Management first reported a position in PLSE in Q3 2025 and has held it in 5 quarters since. The position peaked at $20.9M in Q2 2026. 142 funds tracked by Wall St. Rank hold PLSE as of Q3 2026.

  • Portolan Capital Management held 288,356 shares of Pulse Biosciences worth $14.4M as of Q3 2026.
  • Portolan Capital Management sold 464,977 Pulse Biosciences shares in Q3 2026, an estimated $19.6M.
  • Pulse Biosciences made up 0.59% of Portolan Capital Management's portfolio in Q3 2026, its #61 holding.
  • Portolan Capital Management first reported a position in Pulse Biosciences in Q3 2025 and has held it in 5 quarters since.
  • Portolan Capital Management's Pulse Biosciences position peaked at $20.9M in Q2 2026.
  • 142 funds tracked by Wall St. Rank held Pulse Biosciences as of Q3 2026.

Based on Portolan Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.